open access
Obesity — a still underestimated risk factor during antenatal corticosteroids therapy
Affiliations- Chair and Department of Obstetrics and Pathology of Pregnancy, Medical University of Lublin, Poland
- Chair and Department of Internal Diseases, Medical University of Lublin, Poland
open access
Abstract
Pregnant obese patients are at a greater risk of developing gestational diabetes (GDM). We present a case of an obese patient who developed GDM G2 and periventricular leukomalacia in the neonate after antenatal corticosteroids (ACS) treatment. We suggest that routine blood glucose monitoring should be considered during a course of prenatal steroid therapy in all patients in a higher risk group for glucose intolerance. In cases of hyperglycemia, intensive insulin therapy should be advised. More research and new recommendations are needed on antenatal glucocorticoids (GCS), obesity, and GDM.
Abstract
Pregnant obese patients are at a greater risk of developing gestational diabetes (GDM). We present a case of an obese patient who developed GDM G2 and periventricular leukomalacia in the neonate after antenatal corticosteroids (ACS) treatment. We suggest that routine blood glucose monitoring should be considered during a course of prenatal steroid therapy in all patients in a higher risk group for glucose intolerance. In cases of hyperglycemia, intensive insulin therapy should be advised. More research and new recommendations are needed on antenatal glucocorticoids (GCS), obesity, and GDM.
Keywords
gestational diabetes mellitus; corticosteroids; obesity; pregnancy; insulin therapy
About this articleTitle
Obesity — a still underestimated risk factor during antenatal corticosteroids therapy
Journal
Issue
Article type
Clinical vignette
Published online
2022-11-28
Page views
179
Article views/downloads
123
DOI
10.5603/GP.a2022.0132
Pubmed
Keywords
gestational diabetes mellitus
corticosteroids
obesity
pregnancy
insulin therapy
Authors
Aleksandra Stupak
Tomasz Geca
Arkadiusz Krzyzanowski
Maciej Kwiatek
Iwona Slowik-Kwiatkowska
Anna Kwasniewska
References (7)- Bomba-Opoń DA, Godek B, Czekaj L, et al. Hyperglycemia in pregnancy - prevalence and perinatal outcomes. A retrospective multicenter cohort study in Poland. Ginekol Pol. 2022 [Epub ahead of print].
- Ornoy A, Becker M, Weinstein-Fudim L, et al. Diabetes during pregnancy: a maternal disease complicating the course of pregnancy with long-term deleterious effects on the offspring. A clinical review. Int J Mol Sci. 2021; 22(6).
- Rahmi RM, de Oliveira P, Selistre L, et al. Continuous glucose monitoring in obese pregnant women with no hyperglycemia on glucose tolerance test. PLoS One. 2021; 16(6): e0253047.
- Star J, Hogan J, Sosa ME, et al. Glucocorticoid-associated maternal hyperglycemia: a randomized trial of insulin prophylaxis. J Matern Fetal Med. 2000; 9(5): 273–277, doi: 10.1002/1520-6661(200009/10)9:5<273::AID-MFM3>3.0.CO;2-N.
- Herzog M, Cerar LK, Sršen TP, et al. Impact of risk factors other than prematurity on periventricular leukomalacia. A population-based matched case control study. Eur J Obstet Gynecol Reprod Biol. 2015; 187: 57–59.
- Dalfrà MG, Burlina S, Sartore G, et al. Ketoacidosis in diabetic pregnancy. J Matern Fetal Neonatal Med. 2016; 29(17): 2889–2895.
- Myszkowski B, Stawska A, Glogiewicz M, et al. Influence of gestational diabetes in twin pregnancy on the condition of newborns and early neonatal complications. Ginekol Pol. 2022 [Epub ahead of print].
